Prosecution Insights
Last updated: November 04, 2026
Application No. 18/038,576

SCAR TREATMENT COMPOSITION

Non-Final OA §102§103§112
Filed
May 24, 2023
Priority
Nov 25, 2020 — provisional 63/118,045 +1 more
Examiner
DAVIS, RUTH A
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Topix Pharmaceuticals, Inc.
OA Round
3 (Non-Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
560 granted / 919 resolved
+0.9% vs TC avg
Strong +31% interview lift
Without
With
+31.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
44 currently pending
Career history
967
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
36.5%
-3.5% vs TC avg
§102
15.6%
-24.4% vs TC avg
§112
27.3%
-12.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 919 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 4, 2026 has been entered. Claims 1 – 3, 5, 7 – 9, 21 – 22, 25, 31 – 33, 35 – 36, 43, 51 are pending; claims 36, 43, 51are withdrawn; claims 1 – 3, 5, 7 – 9, 21 – 22, 25, 31 – 33 and 35 have been considered on the merits. All arguments have been fully considered. Information Disclosure Statement The information disclosure statement (IDS) submitted on August 4, 2026, is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 7 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Previous rejections over claims 8 and 35 are withdrawn due to the amendment clarifying Markush language and scope in claim 8; and clarifying an antioxidant component in claim 35. Claim 7 is drawn to a composition however is rendered indefinite for reciting an amount of antioxidant that is outside (or greater than) the range recited in the claim on which it depends, thereby broadening the scope of the claim on which it depends. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 – 3, 5, 7 – 9, 21 – 22, 25, 31 – 33 and 35 are rejected under 35 U.S.C. 102a1 and 102a2 as being anticipated by Obagi et al. (US 9763976). Regarding claims 1, 7, 21 - 22, 31, 33 and 35 Obagi teaches topical compositions comprising silicon based components such as dimethicone polymers (carriers); 0.01 – 1% proteolytic enzymes; and antioxidants such as 0.1 – 0.5% epigallocatechin 3-gallate (EGCG); wherein the compositions are in the form of gel, lotion, suspensions, foam or powder (indicating homogenous compositions and those with less than 10% or 8% water) (abstract, col.3 line 19 – 20, col.5 line 22 – 35, col.6 line 60 – 65, col.9 line 39 0 42, col.15 line 7, col.24 line 15). Regarding claim 2, the enzymes may be papain and/or bromelain (col.5 line 29 - 35, examples). Regarding claim 3, the composition are disclosed to contain the same amount claimed by applicant, indicating they are present in an effective amounts for scavenging overproduction of scar forming proteins and tissues. Regarding claims 5, 8 and 9, additional antioxidants include green tea epigallocatechin, catechin, epicatechin, CoffeeBerry® (caffeic acid), turmeric (p-coumeric acid), luteolin, quercitin, taxifolin, heseridin, apigenin, naringenin, chrysin, glutathione, tocopherol and/or allantoin (col.3 line 14 – 38; col.6 line 59 – 62). Regarding claim 25, the compositions may further include sunscreen (col.1 line 55 – 60). Regarding claim 32, the composition does not require urea, therefore has less than 8% urea. Therefore, the reference anticipates the claimed subject matter. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1 – 3, 5, 7 – 9, 21 – 22, 25, 31 – 33 and 35 remain rejected under 35 U.S.C. 103 as being unpatentable over Aliyar et al. (US 2015/0141389) in view of Perricone et al. (US 2017/0189326). Regarding claims 1, 2, 5, 7 and 31, Aliyar teaches topical drug delivery formulations comprising occlusive agents such as silicon-based components and at least one active to be delivered through the skin for therapeutic or cosmetic purposes (abstract, 0056, 0069). Active agents include proteases (proteolytic enzymes) such as papain and bromelain (0065) and antioxidants (0052). The formulation may be prepared with or without water, which includes less than 10% or less than 8% water (0080, examples 1-6). Aliyar does not teach the composition wherein the active antioxidant is green tea polyphenols in the claimed amount. However, Aliyar teaches active agents to be delivered include antiaging agents (0063) or plant extracts such as oolong (green) tea extract (0066). Perricone teaches topical compositions comprising antioxidants, specifically green tea catechins (polyphenols), for the purpose of treating aging skin (antiaging agents) (abstract), wherein the green tea catechins include epicatechin, epigallocatechin, epicatechin gallate, gallocatechin gallate and epigallocatechin gallate (0007, 0027, claims). Perricone teaches including antioxidants at varying amounts depending on the nature of condition to be treated, severity and user’s skin type, with typical amounts ranging from 0.121 – 6.05% (0015), which includes the claimed ranged. Perricone specifically teaches EGCG may be included in the amount of 0.001 - 0.1%. At the time the claims were filed, when following the teachings of the combined prior art, it would have been obvious to one of ordinary skill in the art to optimize the amount of antioxidants according to these factors and with a reasonable expectation for successfully obtaining an effective topical composition for treating skin. Moreover, at the time the claims were filed one of ordinary skill in the art would have been motivated to include the claimed green tea catechins as the active agent in the delivery formulation of Aliyar since they were well known and used antioxidants and antiaging agents delivered through the skin for therapeutic and cosmetic purposes, and with a reasonable expectation for successfully obtaining an effective topical composition. Regarding the amount of enzyme, it is initially noted that the claims do not require any enzyme as the amount includes 0%. Notwithstanding, Aliyar does not teach the composition comprising the claimed amount of enzyme. However, Aliyar teaches the compositions may be applied to treat scars (0029). In this regard, the active components can be added in amounts effective for its relevant purpose, or treating scars, and are interpreted as result effective variables. As such, at the time the claims were filed, it would have been obvious to one of ordinary skill in the art to optimize the concentration of actives (or enzymes) as a matter of routine practice and experimentation, and with a reasonable expectation for successfully obtaining an effective topical composition. Regarding claim 3, Aliyar teaches the compositions are typically applied to treat scars (0029). In this regard, the active components can be added in amounts effective for its relevant purpose, or treating scars, and are interpreted as result effective variables. Regarding claims 8 – 9, Aliyar teaches additional antioxidants may be included in the compositions, such as glutathione, tocopherol, allantoin (0052, 0064); while Perricone teaches including caffeic acid, tocopherol (0021, 0044). Regarding claim 21, Aliyar teaches including stabilizing agents (0072) and a silicone organic elastomer blend included in a silicone or organic carrier fluid such as isodecylneopentanoate, dimethicone/bis-isobutyl propylene glycol cross polymer, polyethylene glycol-12 dimethicone/bis-isobutyl propylene glycol-20 cross polymer and combinations thereof (0007). Regarding claim 25, Aliyar teaches other active agents may be included such as sunscreens, antibiotics, steroids or hydroquinone (0052, 0058, 0062, claims). Regarding claim 32, neither Aliyar nor Perricone require urea in the compositions, which is less than about 8% urea. Regarding claims 33 and 35, Aliyar teaches the compositions may be homogenous suspensions (0079). Thus, the invention as a whole is prima facie obvious over the references, especially in the absence of evidence to the contrary. Response to Arguments Applicant argues that the prior art fails to teach the claimed amount of enzyme; that Aliyar does not disclose a relationship of a proteolytic enzyme and any result and is therefore not a result effective variable; and that Aliyar is generic to the amount and type of enzyme, thereby encompassing an enormous number of possible enzymes in a long list. However, the claims are drawn to 0 - 1% of enzyme, which includes no enzyme at all, indicating that neither the protease nor the amount thereof is critical to the invention or the claims. Further the claim recites "proteolytic enzyme" which encompasses an enormous list of possible actives spanning extracts from plants, bacteria, fungi and animals; that break down into seven broad groups; function in food digestion, immune system regulation, blood clotting, inflammation, pain relief, cancer progression; and are highly diverse. Thus, the claims are commensurate in scope with the prior art in terms of breadth of scope. Regarding the amount of enzyme, while Aliyar teaches the active can be included at 0.001 - 50%, other ranges are recited to include 0.05 - 10% (0033) which would have been readily optimized by one of ordinary skill in the art according to preferred use. It is noted that while applicant argues the range does not "invite optimization" it is noted that the claims do not require including enzymes at all, as it recites "0 wt.% - 1 wt.%." Applicant argues that Aliyar does not teach green tea polyphenols or EGCG and therefore does not teach a relationship of EGCG and a particular result or that EGCG is a result effective variable; and acknowledges Perricone teaches EGCG at 0.001 - 0.1% for antiaging and not scar treatment or relevant results of claims 1 and 35. Regarding the argument that the prior art does not teach EGCG as an active and cannot be a result effective variable, it is initially noted that the rejection is not based on one reference but a combination of references. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Aliyar teaches a silicone based excipient for known actives, which may include antioxidants. In this regard, antioxidants are recognized compounds having a specific active effect that is an antioxidant. In this regard, the antioxidants are specifically identified as active agents having a result of antioxidant activity. Perricone expressly teaches active antioxidants are included in topical compositions for the same result of antioxidant activity in total amounts of 0.121 - 6.05% and specifically 0.001 - 0.1% of EGCG, which overlaps with the claimed amount (0015, 0027). It is maintained that since the references teach the antioxidant is an active component of the composition, at the time the claims were filed, one of ordinary skill in the art would have been motivated to optimized the amount of the EGCG active as a matter of routine practice and with a reasonable expectation for successfully obtaining an effective topical composition. Regarding the argument that Perricone does not teach the function of treating scars, it is noted that the argued intended use of the claimed composition does not patentably distinguish the composition, per se, since such undisclosed use is inherent in the reference composition. In order to be limiting, the intended use must create a structural difference between the claimed composition and the composition of the prior art. In the instant case, the intended use fails to create a structural difference, thus, the intended use is not limiting. Please note that when applicant claims a composition in terms of function, and the composition of the prior art appears to be the same, the Examiner may make rejections under both 35 U.S.C 102 and 103 (MPEP 2112). Applicant argues that the prior art fails to recognize that green tea polyphenols soothe irritation caused by protease; and as such, that the claimed amounts of enzyme and green tea polyphenol are new and cannot be recognized result effective variables. However, this argument fails to persuade. Initially, the claims recite 0 - 1% of protease, which includes 0% enzyme, or no enzyme at all. Further, the prior art recognizes EGCG as an antioxidant, which by definition has antioxidant activity, and an active component in topical compositions, and is therefore considered a recognized result effective variable. Regarding the argued function of the two components, it is maintained that the intended use of a composition does not patentably distinguish the composition, per se, since such undisclosed use is inherent in the reference composition. In order to be limiting, the intended use must create a structural difference between the claimed composition and the composition of the prior art. In the instant case, the intended use fails to create a structural difference, thus, the intended use is not limiting. Please note that when applicant claims a composition in terms of function, and the composition of the prior art appears to be the same, the Examiner may make rejections under both 35 U.S.C 102 and 103 (MPEP 2112). In addition, it is reiterated that the reason or motivation to modify the reference may often suggest what the inventor has done, but for a different purpose or to solve a different problem. It is not necessary that the prior art suggest the combination to achieve the same advantage or result discovered by applicant (MPEP 2144 (IV)). Thus, for these reasons and those stated in the rejections above, the claims are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUTH A DAVIS whose telephone number is (571)272-0915. The examiner can normally be reached Monday - Friday (8am - 4pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUTH A DAVIS/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

May 24, 2023
Application Filed
Dec 03, 2025
Non-Final Rejection mailed — §102, §103, §112
Mar 03, 2026
Response Filed
May 04, 2026
Final Rejection mailed — §102, §103, §112
Aug 04, 2026
Request for Continued Examination
Aug 05, 2026
Response after Non-Final Action
Aug 19, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778160
Method and Composition For Reducing Pathogens in Pet Food Using Lactic Acid Bacteria
6y 6m to grant Granted Nov 03, 2026
Patent 12774459
TRUNCATED MODIFIED RECOMBINANT ADAMTS13 AND USES THEREOF
3y 6m to grant Granted Oct 27, 2026
Patent 12773431
COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS
3y 2m to grant Granted Oct 27, 2026
Patent 12766045
Auto-Biodegradable Absorbent Articles
3y 9m to grant Granted Oct 20, 2026
Patent 12766224
DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUE
1y 5m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+31.0%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 919 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month